Main Menu

The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center. This adaptation process aims to create an optimal host line for manufacturing stabilized RSV F, ensuring stable expression and high protein yields without compromising function or stability.

This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry C3d on the cell surface and can bind and be killed by addition of anti-C3 mAbs. In contrast, further addition of more ofatumumab has only minimal effects.